Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NOTA-ABSCINT-HER2
- Development stage
- Phase 2
- Lead developer
- ABSCINT
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[68Ga]Ga-NOTA-ABSCINT-HER2 is a radiopharmaceutical diagnostic agent developed by Abscint in collaboration with the Centre Henri Becquerel. It consists of a single-domain antibody (sdAb), also known as a nanobody (specifically the 2Rs15d clone), which is conjugated to the chelator NOTA and radiolabeled with the positron emitter Gallium-68 (68Ga). This agent is designed for use with positron emission tomography (PET) to non-invasively detect and quantify the expression of Human Epidermal Growth Factor Receptor 2 (HER2) in patients with breast cancer and other HER2-positive solid tumors. Due to its small molecular size (approximately 15 kDa), the nanobody exhibits rapid blood clearance and high tumor penetration, allowing for high-contrast imaging within one hour of administration. This facilitates the identification of HER2-positive lesions, including metastases, and helps in selecting patients for HER2-targeted therapies.
- Other names
- Gallium-68 NOTA-ABSCINT-HER2Gallium68 NOTA-ABSCINT-HER2Gallium 68 NOTA-ABSCINT-HER268Ga-ABSCINT-HER2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on [68Ga]Ga-NOTA-ABSCINT-HER2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-NOTA-ABSCINT-HER2.